Pediatric cancer incidence among individuals with overgrowth syndromes and overgrowth features: A population‐based assessment in seven million children

Abstract

AbstractBackgroundOvergrowth syndromes (e.g., Beckwith–Wiedemann) are associated with an increased risk of pediatric cancer, although there are few population‐based estimates of risk. There are also limited studies describing associations between other overgrowth features (e.g., hepatosplenomegaly) and pediatric cancer. Therefore, cancer risk among children with these conditions was evaluated with data from a large, diverse population‐based registry linkage study.MethodsThis study includes all live births in Texas during the years 1999–2017. Children with overgrowth features and syndromes were identified from the Texas Birth Defects Registry; children with cancer were identified by linkage to the Texas Cancer Registry. Cox regression models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for the association between each overgrowth syndrome/feature and cancer, which were adjusted for infant sex and maternal age.ResultsIn the total birth cohort (n = 6,997,422), 21,207 children were identified as having an overgrowth syndrome or feature. Children with Beckwith–Wiedemann syndrome were 42 times more likely to develop pediatric cancer (95% CI, 24.20–71.83), with hepatoblastoma being the most common, followed by Wilms tumor. The presence of any isolated overgrowth feature was associated with increased cancer risk (HR, 4.70; 95% CI, 3.83–5.77); associations were strongest for hepatosplenomegaly (HR, 23.04; 95% CI, 13.37–39.69) and macroglossia (HR, 11.18; 95% CI, 6.35–19.70).ConclusionsThis population‐based assessment confirmed prior findings that children with either overgrowth syndromes or features were significantly more likely to develop cancer. Overall, this study supports recommendations for cancer surveillance in children with these conditions and may also inform future research into cancer etiology.